Temozolomide – Lenvatinib cocrystal interface

The Temozolomide – Lenvatinib cocrystal interface refers to the physical and chemical boundary between Temozolomide and Lenvatinib molecules within a single crystalline lattice. This is a pharmaceutical solid-state construct rather than a biological receptor or therapeutic target. In such a cocrystal, the two drugs are typically held together by intermolecular forces like hydrogen bonds, which can modify the solubility, dissolution rate, and stability of the individual components. While Temozolomide is an alkylating agent used for glioblastoma and Lenvatinib is a multi-kinase inhibitor, their cocrystal interface is studied to optimize delivery and potentially enhance the synergistic effects of the combination therapy. Because it is a structural feature of a drug formulation and not a biological entity like a protein or enzyme, it does not possess biological functions or disease roles in the traditional sense.

Other names

TMZ-LEN cocrystalTemozolomide-Lenvatinib crystalline complex

The interface itself does not have a mechanism of action; rather, it represents the supramolecular arrangement of two active pharmaceutical ingredients (APIs) held together by non-covalent interactions such as hydrogen bonding and pi-stacking to improve physicochemical properties.